NKTR
NKTR clinical trials: NEKTAR THERAPEUTICS
Every trial on ClinicalTrials.gov where NEKTAR THERAPEUTICS is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 62
- Trials linked
- 39
- As lead sponsor
- 23
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
NKTR on the catalyst calendar · NKTR registry changes
- Primary completion Nov 26, 2025ActualPhase 2NCT06340360A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients...Nektar Therapeutics · Alopecia AreataCompletedNKTRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 2028Sponsor estimatePhase 3NCT07690371A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic DermatitisNektar Therapeutics · Moderate-to-Severe Atopic DermatitisRecruitingNKTRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 22, 2024ActualPhase 2/Phase 3NCT05664217NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell LymphomaNektar Therapeutics · Non-Hodgkin LymphomaTerminatedNKTRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2028Sponsor estimatePhase 3NCT07711418A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic DermatitisNektar Therapeutics · Moderate-to-Severe Atopic DermatitisRecruitingNKTRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 6, 2025ActualPhase 2NCT06136741A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic DermatitisNektar Therapeutics · Moderate to Severe Atopic DermatitisActive, not recruitingNKTRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 30, 2023ActualPhase 1/Phase 2NCT04616196Study of NKTR 255 in Combination With Cetuximab in Solid TumorsNektar Therapeutics · Head and Neck Squamous Cell CarcinomaCompletedNKTRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 10, 2023ActualPhase 2NCT04433585A Study of LY3471851 in Adults With Systemic Lupus Erythematosus (SLE)Nektar Therapeutics · Systemic Lupus ErythematosusCompletedNKTRLeadLLYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 11, 2021ActualPhase 1NCT04646044A Placebo Controlled Trial of Bempegaldesleukin (BEMPEG; NKTR-214) With Standard of Care in Patients With Mild COVID-19Nektar Therapeutics · Covid-19CompletedNKTRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 21, 2021ActualPhase 1NCT04119557A Study of LY3471851 in Participants With PsoriasisNektar Therapeutics · PsoriasisCompletedNKTRLeadLLYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 24, 2022ActualPhase 1NCT04081350A Study of LY3471851 in Participants With EczemaNektar Therapeutics · Dermatitis, AtopicCompletedNKTRLeadLLYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 23, 2023ActualPhase 1NCT05565729A Phase I Study of LY3471851 in Healthy ParticipantsNektar Therapeutics · HealthyCompletedNKTRLeadLLYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 6, 2022ActualPhase 1NCT04998487A Single-Dose Study of LY3471851 in Healthy ParticipantsNektar Therapeutics · HealthyCompletedNKTRLeadLLYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 20, 2019ActualPhase 1NCT04380324A Study of NKTR-358 (LY3471851) in Healthy ParticipantsNektar Therapeutics · HealthyCompletedNKTRLeadLLYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 6, 2020ActualPhase 1NCT04133116A Study of LY3471851 in Healthy ParticipantsNektar Therapeutics · HealthyCompletedNKTRLeadLLYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 29, 2019ActualPhase 1NCT03556007A Study of NKTR-358 (LY3471851) in Participants With Systemic Lupus Erythematosus (SLE)Nektar Therapeutics · Systemic Lupus ErythematosusCompletedNKTRLeadLLYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 9, 2022ActualPhase 2NCT04677179A Study of LY3471851 in Adult Participants With Moderately to Severely Active Ulcerative Colitis (UC)Nektar Therapeutics · Colitis, UlcerativeTerminatedNKTRLeadLLYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 24, 2023ActualPhase 1NCT04136756NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin LymphomaNektar Therapeutics · Multiple MyelomaCompletedNKTRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2020ActualPhase 3NCT02915744A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have...Nektar Therapeutics · MetastasisCompletedNKTRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 22, 2022ActualPhase 3NCT04410445Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of...Nektar Therapeutics · MelanomaTerminatedNKTRLeadBMYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 9, 2022ActualPhase 2NCT03785925A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Locally Advanced or...Nektar Therapeutics · Urinary Bladder NeoplasmCompletedNKTRLeadBMYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 7, 2022ActualPhase 3NCT03729245A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine...Nektar Therapeutics · Renal Cell CarcinomaTerminatedNKTRLeadBMYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 28, 2022ActualPhase 1/Phase 2NCT02983045A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With...Nektar Therapeutics · MelanomaCompletedNKTRLeadBMYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 5, 2022ActualPhase 1/Phase 2NCT03138889Bempegaldesleukin and Pembrolizumab With or Without Chemotherapy in Locally Advanced or Metastatic Solid TumorsNektar Therapeutics · Non-Small Cell Lung CancerTerminatedNKTRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 9, 2022ActualPhase 1/Phase 2NCT03435640REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor MalignanciesNektar Therapeutics · MelanomaTerminatedNKTRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 22, 2022ActualPhase 2/Phase 3NCT04969861BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36)Nektar Therapeutics · Metastatic Head and Neck CancerTerminatedNKTRLeadMRKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 37 more in this window; the full list is part of TrialScanner.
Unlock with TrialScanner